x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0012396
| Product Information | |
|---|---|
| Clonality | Monoclonal |
| Isotype | IgG |
| Host Species | Rabbit |
| Reactivity | Human, Mouse, Rat, Monkey |
| Applications | WB |
| Product Description | Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human PCK1 protein. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | PCK1 |
| UniProt No. | P35558 |
| Gene ID | 5105 |
| Gene Description | Phosphoenolpyruvate carboxykinase 1 is a cytosolic enzyme responsible for the conversion of oxaloacetate to phosphoenolpyruvate. PCK1 is involved in controlling the rate-limiting step of gluconeogenesis in the liver, which generates glucose from non-carbohydrate substrates such as lactate and glycerol. The deacetylase SirT1 stimulates transcription of PCK1 and glucose-6-phosphatase to activate gluconeogenesis. Depending on nutritional state, Stat3 can inhibit PCK1 and glucose-6-phosphatase expression and suppress gluconeogenesis. Relatively high glucose concentration can result in acetylation of PCK1 by P300 acetyltransferase, promoting an interaction between PCK1 and the E3 ligase UBR5 that leads to the PCK1 destabilization. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
